Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Change in Accured Expenses (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Change in Accured Expenses for 3 consecutive years, with -$673000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 15.03% to -$673000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$839000.0, a 61.85% increase, with the full-year FY2024 number at -$1.2 million, down 67.89% from a year prior.
  • Change in Accured Expenses was -$673000.0 for Q3 2025 at Mereo BioPharma, down from $1.9 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.2 million in Q2 2023 to a low of -$3.1 million in Q1 2023.
  • A 3-year average of -$185000.0 and a median of -$706000.0 in 2024 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 58.79% in 2024; the steepest drop was 442.47% in 2024.
  • Mereo BioPharma's Change in Accured Expenses stood at -$1.7 million in 2023, then skyrocketed by 58.79% to -$706000.0 in 2024, then increased by 4.67% to -$673000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Change in Accured Expenses are -$673000.0 (Q3 2025), $1.9 million (Q2 2025), and -$1.4 million (Q1 2025).